Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Health Promotion and Disease Prevention Research Centers: FY08 Special Interest Project Competitive Supplements, Program Announcement Number (PA) DP 08-002, 35393 [E8-14082]
Download as PDF
<![CDATA[
35393
Federal Register / Vol. 73, No. 121 / Monday, June 23, 2008 / Notices
chronically infected with hepatitis B
virus. Each year, there are
approximately 8,000–10,000 hepatitis C
virus infection related deaths and
3,000–5,000 hepatitis B virus infection
related deaths.
Current surveillance activities are not
designed to monitor long-term outcomes
and merely report diagnosed cases of
hepatitis B and hepatitis C virus
infections. In order to investigate longterm effects of new therapies for chronic
viral hepatitis B and C infections, we
need longitudinal observational cohorts
of persons chronically infected with
hepatitis B and/or C virus. Information
from longitudinal cohorts of patients
with chronic hepatitis B and C virus
infection will provide an understanding
of the spectrum and natural history and,
the public health impact of chronic
hepatitis disease.
adherence to prescribed therapy, which
is essential in order to be able to
correctly interpret clinical outcomes
data. These data will be used to describe
the spectrum and natural history of
disease associated with chronic
hepatitis B and C virus infection, to
determine the extent of health burden
and mortality related to chronic viral
hepatitis, describe the characteristics of
persons in care for chronic viral
hepatitis infection, describe access to
and effectiveness of recommended
preventive and therapeutic
interventions, and evaluate ongoing risk
behaviors and their impact on health
outcomes.
Participation in this data collection is
voluntary and there is no cost to
respondents other than their time.
The proposed project will establish a
longitudinal observational cohort of
patients with chronic viral hepatitis in
one or more clinical centers. A patient
behavior questionnaire will be included
with the clinical information that
physicians routinely collect when
evaluating and examining a patient (i.e.
during physician-patient interactions).
The information linking behaviors with
the clinical information from this
longitudinal study will enable better
care and management of persons with
chronic hepatitis B and C virus
infections and reduce hepatitis-related
mortality.
The total annual burden for this
project is expected to be 500 hours. The
information to be collected in the
patient behavior questionnaire includes
demographic data, alcohol or drug use,
access to care, quality of life, and
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Patients with chronic hepatitis B or C virus infection ......................................
Dated: June 13, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E8–14154 Filed 6–20–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and ControlSpecial
Emphasis Panel (SEP): Health
Promotion and Disease Prevention
Research Centers: FY08 Special
Interest Project Competitive
Supplements, Program Announcement
Number (PA) DP 08–002
mmaher on PROD1PC70 with NOTICES
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
01:51 Jun 21, 2008
Jkt 214001
1000
1
Average burden per
response
(in hours)
Total burden
(in hours)
30/60
500
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to ‘‘Health Promotion and Disease
Prevention Research Centers: FY08 Special
Interest Project Competitive Supplements,
PA DP 08–002.’’
Contact Person for More Information: K.
Ann Berry, Senior Scientist, CDC, 1600
Clifton Road, NE., Mailstop E20, Atlanta, GA
30333, Telephone (404) 498–2503.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: June 16, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office,Centers for Disease Control and
Prevention.
[FR Doc. E8–14082 Filed 6–20–08; 8:45 am]
Time and Date: 8 a.m.–5 p.m., July 10,
2008 (Closed).
Place: Grand Hyatt Atlanta, 3300 Peachtree
Road, NE., Atlanta, GA 30305, Telephone:
(404) 237–1234.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to ‘‘Spina Bifida Patient Registry
Demonstration Project (U01), PA DP 08–
001.’’
For More Information Contact: Gwendolyn
Cattledge, Deputy Associate Director for
Science, CDC, 1600 Clifton Road, NE.,
BILLING CODE 4163–18–P
Time and Dates: 8 a.m.–5 p.m., July 9,
2008 (Closed).8 a.m.–5 p.m., July 10, 2008
(Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
VerDate Aug<31>2005
Number of
responses per
respondent
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Spina Bifida
Patient Registry Demonstration Project
(U01), Program Announcement
Number (PA) DP 08–001
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
E:\FR\FM\23JNN1.SGM
23JNN1
]]>Agencies
[Federal Register Volume 73, Number 121 (Monday, June 23, 2008)]
[Notices]
[Page 35393]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-14082]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and ControlSpecial
Emphasis Panel (SEP): Health Promotion and Disease Prevention Research
Centers: FY08 Special Interest Project Competitive Supplements, Program
Announcement Number (PA) DP 08-002
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time and Dates: 8 a.m.-5 p.m., July 9, 2008 (Closed).8 a.m.-5
p.m., July 10, 2008 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters to be Discussed: The meeting will include the review,
discussion, and evaluation of applications received in response to
``Health Promotion and Disease Prevention Research Centers: FY08
Special Interest Project Competitive Supplements, PA DP 08-002.''
Contact Person for More Information: K. Ann Berry, Senior
Scientist, CDC, 1600 Clifton Road, NE., Mailstop E20, Atlanta, GA
30333, Telephone (404) 498-2503.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: June 16, 2008.
Elaine L. Baker,
Director, Management Analysis and Services Office,Centers for Disease
Control and Prevention.
[FR Doc. E8-14082 Filed 6-20-08; 8:45 am]
BILLING CODE 4163-18-P
